AAA617
Sponsors
Novartis Pharmaceuticals
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate Cancer (mCRPC)Oligometastatic Prostate Cancer (OMPC)PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based ChemotherapyProstate CancerProstatic Cancer, Castration-ResistantProstatic Neoplasm
Phase 1
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
RecruitingNCT06531499
Start: 2024-11-11End: 2028-11-24Target: 106Updated: 2025-12-31
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
RecruitingNCT07226986
Start: 2025-12-05End: 2029-09-13Target: 123Updated: 2026-04-01
Phase 2
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Active, not recruitingNCT05849298
Start: 2024-01-03End: 2026-12-23Updated: 2026-03-03
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
RecruitingNCT06004661
Start: 2024-04-04End: 2026-06-17Target: 20Updated: 2026-03-06
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Active, not recruitingNCT06894511
Start: 2025-09-11End: 2029-04-09Updated: 2026-02-17
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RecruitingNCT07047118
Start: 2025-07-03End: 2028-11-04Target: 130Updated: 2026-04-01